Literature DB >> 26482514

Infectious complications in combined colon resection and ablation of colorectal liver metastases.

Cathryn A Doughtie1, Jacob D Edwards1, Prejesh Philips1, Steven C Agle1, Charles R Scoggins1, Kelly M McMasters1, Robert C G Martin2.   

Abstract

BACKGROUND: The multifactorial incidence of infectious complications carries considerable consequences for patients undergoing more extensive surgery with intent to cure metastatic colorectal cancer. Advances in ablation techniques have emerged as an efficacious method in regional control for liver metastasis from colorectal cancer; however, the degree of increased risk of infectious complications when ablation is performed in combination with colon resection has not been defined.
METHODS: An analysis of a single institution's prospective database from August 1998 to December 2012 was performed for patients undergoing colon resection. Patients were stratified into a colon resection combined with either microwave ablation (MWA) or radiofrequency ablation (RFA) compared to a colon resection only group. Variables included baseline clinicopathologic data, type of operation, complication grade, and infectious outcome. Fisher exact test, Student t test, and analysis of variance were used to detect significance levels of P values less than .05.
RESULTS: A total of 132 patients with colon cancer of various origins were identified. The group of colon resection combined with RFA and/or MWA was 53 patients (34 male:19 female) and was compared to a matched group of 79 patients (40 male:39 female) who underwent colon resection alone. Median age (58 vs 60 years; P = .209), complication rate (60.7% vs 62.5%; P = .722), infection rate (28.7% vs 35.4%; P = 1.0), mean blood loss (352.7 vs 468.4 mL; P = .452), mean blood transfused (1.36 vs .76 U; P = .247), and receipt of neoadjuvant chemotherapy (47.1% vs 51.85%; P = .724) were all similar between the ablation group and colon only group, respectively. Transfusion rate was higher in the ablation group (39.6% vs 18.9%; P = .016). Overall complication rate was 60.6%, with 32.6% infections. One mortality was observed in each group. High-grade (grade, III to V) complications (35.8% vs 18.9%; P = .0112) and liver-specific complications (n = 4; P = .024) were significantly increased in the combined ablation group.
CONCLUSIONS: Combining MWA or RFA techniques with colon resection for liver metastasis appears to have similar infectious and overall complication rates when compared to performing an isolated resection of the primary colon cancer alone, although there may be a higher degree of complication seen in the more aggressive approach for curative intent in patients with colorectal liver metastasis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal liver metastasis; Infection; Microwave ablation; Radiofrequency ablation

Mesh:

Year:  2015        PMID: 26482514     DOI: 10.1016/j.amjsurg.2015.07.012

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Postoperative Infectious Complications Impact Long-Term Survival in Patients Who Underwent Hepatectomies for Colorectal Liver Metastases: a Propensity Score Matching Analysis.

Authors:  Riccardo Memeo; Vito de Blasi; Rene Adam; Diane Goéré; Alexis Laurent; Nicola de'Angelis; Tullio Piardi; Emilie Lermite; Astrid Herrero; Francis Navarro; Antonio Sa Cunha; Patrick Pessaux
Journal:  J Gastrointest Surg       Date:  2018-07-10       Impact factor: 3.452

2.  Synchronous Colorectal Liver Metastases considering Infectious Complications: Simultaneous or Delayed Surgery?

Authors:  Lijun Huang; Xiao Tang; Jiafeng Fang; Zongheng Zheng; Hongbo Wei
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

3.  Incidence and Risk Factors for Organ/Space Infection after Radiofrequency-Assisted Hepatectomy or Ablation of Liver Tumors in a Single Center: More than Meets the Eye.

Authors:  Ioannis Karavokyros; Stamatios Orfanos; Anastasios Angelou; Antonia Meropouli; Dimitrios Schizas; John Griniatsos; Emmanouil Pikoulis
Journal:  Front Surg       Date:  2017-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.